Role of the erythropoietin receptor in Lung Cancer cells: erythropoietin exhibits angiogenic potential.

摘要: Background: Recombinant human erythropoietin (rHuEPO), a hormone regulating the proliferation and differentiation of erythroid cells, is one prescription drugs used to treat cancer-associated anemia. However, administration rHuEPO cancer patients has been reported be associated with decreased survival, mechanism by which it acts remains controversial. The present study aimed investigate expression EPO-receptor in lung cell lines whether treatment affected its growth migration. Moreover, angiogenic effects were also explored vivo. Methods: Expression was measured Western blotting enzyme linked immunosorbent assays (ELISAs). Proliferation cells monitored presence rHuEPO. Human umbilical vein endothelial (HUVECs) for tube formation vitro, transwell migration performed detect under treatment. Matrigel plug technology employed observe both nude mice Matrigel-containing H838 or H1975. Microvessel density (MVD) using CD31 Immunohistochemistry (IHC) staining. Results: (EPO-R) only detected H1339 ELISA. EPO-R protein all blotting, contradiction ELISA results. not promoted HUVEC vitro significantly induced new blood vessels Furthermore, did antagonize inhibitory Afatinib (epidermal factor receptor-tyrosine kinase inhibitor; EGFR-TKI) simultaneous In 3D co-culture model, enhance secretion vascular (VEGF) fibroblast line MRC-5. Conclusions: We have shown that role EPO goes beyond erythropoiesis, playing strong angiogenesis participating vessel models. Thus, may raise risk thrombosis metastasis Additionally, our results suggest studies commercially available antibodies should reexamined; some these fact recognize EPO-R.